EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 212 / Numéro 3-4 (2018) Biologie Aujourd'hui, 212 3-4 (2018) 61-67 Références
Accès gratuit
Numéro
Biologie Aujourd'hui
Volume 212, Numéro 3-4, 2018
Page(s) 61 - 67
DOI https://doi.org/10.1051/jbio/2019011
Publié en ligne 11 avril 2019
  • André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., Rossi, B., Remark, R., Breso, V., Bonnet, E., Habif, G., Guia, S., Lalanne, A.I., Hoffmann, C., Lantz, O., Fayette, J., Boyer-Chammard, A., Zerbib, R., Dodion, P., Ghadially, H., Jure-Kunkel, M., Morel, Y., Herbst, R., Narni-Mancinelli, E., Cohen, R.B., Vivier, E. (2018). Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell , 175, 1731-1743 e1713. [Google Scholar]
  • Benson, D.M., Jr., Bakan, C.E., Zhang, S., Collins, S.M., Liang, J., Srivastava, S., Hofmeister, C.C., Efebera, Y., André, P., Romagne, F., Bléry, M., Bonnafous, C., Zhang, J., Clever, D., Caligiuri, M.A., Farag, S.S. (2011). IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood , 118, 6387-6391. [CrossRef] [Google Scholar]
  • Carlsten, M., Korde, N., Kotecha, R., Reger, R., Bor, S., Kazandjian, D., Landgren, O., Childs, R.W. (2016). Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma. Clin Cancer Res , 22, 5211-5222. [CrossRef] [PubMed] [Google Scholar]
  • Chen, D.S., Mellman, I. (2017). Elements of cancer immunity and the cancer-immune set point. Nature , 541, 321-330. [CrossRef] [PubMed] [Google Scholar]
  • Childs, R.W., Carlsten, M. (2015). Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: The force awakens. Nat Rev Drug Discov , 14, 487-498. [CrossRef] [PubMed] [Google Scholar]
  • Daeron, M., Jaeger, S., Du Pasquier, L., Vivier, E. (2008). Immunoreceptor tyrosine-based inhibition motifs: A quest in the past and future. Immunol Rev , 224, 11-43. [CrossRef] [PubMed] [Google Scholar]
  • Guillerey, C., Huntington, N.D., Smyth, M.J. (2016). Targeting natural killer cells in cancer immunotherapy. Nat Immunol , 17, 1025-1036. [CrossRef] [PubMed] [Google Scholar]
  • Imai, K., Matsuyama, S., Miyake, S., Suga, K., Nakachi, K. (2000). Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet , 356, 1795-1799. [CrossRef] [PubMed] [Google Scholar]
  • Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., Minato, N. (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA , 99, 12293-12297. [Google Scholar]
  • Kohrt, H.E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., Waller, E., Ugolini, S., Vivier, E., Romagne, F., Lévy, R., Bléry, M., André, P. (2014). Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood , 123, 678-686. [CrossRef] [Google Scholar]
  • Mamessier, E., Sylvain, A., Thibult, M.L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Goncalves, A., André, P., Romagne, F., Thibault, G., Viens, P., Birnbaum, D., Bertucci, F., Moretta, A., Olive, D. (2011). Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest , 121, 3609-3622. [CrossRef] [PubMed] [Google Scholar]
  • Orange, J.S., Ballas, Z.K. (2006). Natural killer cells in human health and disease. Clin Immunol , 118, 1-10. [CrossRef] [PubMed] [Google Scholar]
  • Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., Moretta, L., Moretta, A., Marcenaro, E. (2017). Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J Allergy Clin Immunol , 139, 335-346 e3. [CrossRef] [Google Scholar]
  • Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., André, P., Dieu-Nosjean, M.C., Alifano, M., Régnard, J.F., Fridman, W.H., Sautes-Fridman, C., Cremer, I. (2011). Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res , 71, 5412-5422. [CrossRef] [Google Scholar]
  • Romagne, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D.M., Jr., Blaser, B.W., Della Chiesa, M., Moretta, A., Vivier, E., Caligiuri, M.A., Velardi, A., Wagtmann, N. (2009). Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood , 114, 2667-2677. [CrossRef] [PubMed] [Google Scholar]
  • Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F., Velardi, A. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science , 295, 2097-2100. [CrossRef] [Google Scholar]
  • Ruggeri, L., Mancusi, A., Burchielli, E., Capanni, M., Carotti, A., Aloisi, T., Aversa, F., Martelli, M.F., Velardi, A. (2008). NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis , 40, 84-90. [CrossRef] [PubMed] [Google Scholar]
  • Ruggeri, L., Urbani, E., André, P., Mancusi, A., Tosti, A., Topini, F., Bléry, M., Animobono, L., Romagne, F., Wagtmann, N., Velardi, A. (2016). Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica , 101, 626-633. [CrossRef] [PubMed] [Google Scholar]
  • Talebian Yazdi, M., van Riet, S., van Schadewijk, A., Fiocco, M., van Hall, T., Taube, C., Hiemstra, P.S., van der Burg, S.H. (2016). The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget , 7, 3477-3488. [PubMed] [Google Scholar]
  • Tursz, T., Dokhelar, M.C., Lipinski, M., Amiel, J.L. (1982). Low natural killer cell activity in patients with malignant lymphoma. Cancer , 50, 2333-2335. [CrossRef] [PubMed] [Google Scholar]
  • Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L., Yokoyama, W.M., Ugolini, S. (2011). Innate or adaptive immunity? The example of natural killer cells. Science , 331, 44-49. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.